Shruti Gaggar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shruti Gaggar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adile Orhan
Center for Surgical Science, Department of Surgery, Zealand University Hospital, Lykkebækvej 1, 4600 Køge, Denmark
3 shared publications - Hans Raskov
Center for Surgical Science, Zealand University Hospital, Køge, Denmark
3 shared publications Ismail Gögenur
Center for Surgical Science, Zealand University Hospital, Køge, 4600, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, 2200, Denmark
2 shared publications- Ali Salanti
Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication Asma Tajik
Center for Surgical Science, Zealand University Hospital, Køge, 4600, Denmark
1 shared publication- Ismail Gögenur
Department of Surgery, Centre for Surgical Science Zealand University Hospital Køge Denmark
1 shared publication
Latest Publications
- Open Access
- 25 November 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 180, 30-51
Metabolic switch in cancer – Survival of the fittest
- 25 November 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 180, 30-51
Open AccessMetabolic switch in cancer – Survival of the fittest
- Open Access
- 3 May 2022
- Published by Springer Nature in Oncogenesis
- Vol. 11 (1) , 1-16
Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy
Neutrophils are central mediators of innate and adaptive immunity and first responders to tissue damage. Although vital to our health, their activation, function, and resolution are critical to preventing chronic inflammation that may contribute to carcinogenesis. Cancers are associated with the expansion of the neutrophil compartment with an escalation in the number of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in the peripheral circulation and tumor microenvironment. Although phenotypically similar to classically activated neutrophils, PMN-MDSC is pathologically activated and immunosuppressive in nature. They dynamically interact with other cell populations and tissue components and convey resistance to anticancer therapies while accelerating disease progression and metastatic spread. Cancer-associated neutrophilia and tumor infiltration of neutrophils are significant markers of poor outcomes in many cancers. Recently, there has been significant progress in the identification of molecular markers of PMN-MDSC providing insights into the central role of PMN-MDSC in the local tumor microenvironment as well as the systemic immune response in cancer. Further advances in sequencing and proteomics techniques will improve our understanding of their diverse functionalities and the complex molecular mechanisms at play. Targeting PMN-MDSC is currently one of the major focus areas in cancer research and several signaling pathways representing possible treatment targets have been identified. Positive results from preclinical studies clearly justify the current investigation in drug development and thus novel therapeutic strategies are being evaluated in clinical trials. In this review, we discuss the involvement of PMN-MDSC in cancer initiation and progression and their potential as therapeutic targets and clinical biomarkers in different cancers.
- 3 May 2022
- Published by Springer Nature in Oncogenesis
- Vol. 11 (1) , 1-16
Open AccessNeutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy
Neutrophils are central mediators of innate and adaptive immunity and first responders to tissue damage. Although vital to our health, their activation, function, and resolution are critical to preventing chronic inflammation that may contribute to carcinogenesis. Cancers are associated with the expansion of the neutrophil compartment with an escalation in the number of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in the peripheral circulation and tumor microenvironment. Although phenotypically similar to classically activated neutrophils, PMN-MDSC is pathologically activated and immunosuppressive in nature. They dynamically interact with other cell populations and tissue components and convey resistance to anticancer therapies while accelerating disease progression and metastatic spread. Cancer-associated neutrophilia and tumor infiltration of neutrophils are significant markers of poor outcomes in many cancers. Recently, there has been significant progress in the identification of molecular markers of PMN-MDSC providing insights into the central role of PMN-MDSC in the local tumor microenvironment as well as the systemic immune response in cancer. Further advances in sequencing and proteomics techniques will improve our understanding of their diverse functionalities and the complex molecular mechanisms at play. Targeting PMN-MDSC is currently one of the major focus areas in cancer research and several signaling pathways representing possible treatment targets have been identified. Positive results from preclinical studies clearly justify the current investigation in drug development and thus novel therapeutic strategies are being evaluated in clinical trials. In this review, we discuss the involvement of PMN-MDSC in cancer initiation and progression and their potential as therapeutic targets and clinical biomarkers in different cancers.
- 1 November 2021
- Published by Elsevier in Cancer Letters
- Vol. 520, 233-242
Natural Killer Cells in Cancer and Cancer Immunotherapy
- 1 November 2021
- Published by Elsevier in Cancer Letters
- Vol. 520, 233-242
Natural Killer Cells in Cancer and Cancer Immunotherapy